Side by side

1. 1.In animal models it appears to increase signalling through the VEGFR2 pathway, which is involved in new blood-vessel formation.
2. 2.It has been reported to interact with nitric oxide and growth-factor pathways in tissue-repair models.
3. 3.Animal studies describe faster closure of tendon, muscle and gut-lining injuries.
4. 4.Proposed mechanisms have not been confirmed in controlled human studies, and the receptor-level target is still debated.

• Tendon and ligament healing (animal models)
• Muscle injury repair (animal models)
• Gut-lining damage and inflammatory bowel models (animal)
• Gastric ulcer models (animal)
• A small number of uncontrolled human reports, mostly in the knee and gut

• Faster histological healing in rat tendon and muscle models
• Reduced ulcer size in rodent gastric-injury models
• Reported improvement in pain scores in small, uncontrolled human case series
• No adequately powered randomised human trial has been published

• Human safety data are minimal, so the true side-effect profile is unknown
• Injection-site irritation reported anecdotally
• Nausea and dizziness reported anecdotally
• Product purity is unregulated in most markets — contamination is a documented problem with research chemicals

Research context only — there is no approved human protocol. Published animal work used doses expressed in micrograms per kilogram, often given by injection for one to four weeks. Widely circulated online 'cycle' numbers come from forums, not from clinical research, and should not be treated as evidence of safety or effectiveness.

Research context only